Schott Pharma has inaugurated production lines for glass vials at its Lebanon, Pennsylvania, USA, site after a $60 million investment.
The lines will increase capacity for both standard and sterile ready-to-use (RTU) glass vials designed to store a variety of drugs, from biologics and other complex injectable therapies to vaccines and emergency room medications.
The new capabilities feature technology for efficient manufacturing and optimised output.
The investment was mostly funded by the Biomedical Advanced Research and Development Authority (BARDA) which aims to strengthen the U.S. pharmaceutical supply chain and ensure reliable domestic production of critical primary packaging.
The expansion increases the site’s annual production capacity for core vials, while more than tripling local capacity for high-value solutions.
Christian Mias, CEO of Schott Pharma, said: “The expansion contributes to Schott Pharma’s long-term global growth strategy, with a strong local-for-local presence in the U.S. and scaled manufacturing capacity for high-value solutions that address key trends in the pharmaceutical industry, such as biologic medications and novel drug formulations.”
In addition to installing new converting lines for core borosilicate glass vials, the expansion in Lebanon included major infrastructure modernisation, line upgrades, and new technology to increase capacity.
The site is one of only two Schott Pharma locations capable of manufacturing Everic pure vials.
The Everic pure specialty vials feature high chemical durability, a homogeneous inner surface, and tight dimensional tolerances to ensure safe containment of complex modalities. Pic source: Schott Pharma and Nils Hendrik Müller.
These vials are highly chemically durable, with a homogeneous inner surface, and tight dimensional tolerances to ensure drug stability throughout their shelf life.
It is also the only site that produces adaptiQ pre‑washed, pre‑sterilised RTU vials, and supplies these containers across the U.S. and globally.
Christopher Cassidy, President of Schott Pharma USA, said: “We would like to express our sincere gratitude to the Biomedical Advanced Research and Development Authority for supporting the expansion of our U.S.-based manufacturing footprint.
“With its new advanced equipment, our site in Lebanon, Pennsylvania is strengthening supply chain resilience in the U.S. and ensuring the availability of primary packaging for critical life-saving therapies for patients throughout our nation.”
